Does Medicare Advantage Cover Losartan?

How Medicare Advantage Part D Covers Losartan

Most Medicare Advantage Prescription Drug (MA-PD) plans cover losartan at the lowest generic tier because the drug lost patent exclusivity and has been generic since 2010. Tier 1 copays in 2024 Medicare plans average $0, $5 per fill; Tier 2 copays average $5, $15. The Centers for Medicare and Medicaid Services (CMS) requires every Part D plan to include at least two drugs in each therapeutic class, and angiotensin receptor blockers (ARBs) are one of the six protected classes in all but name for antihypertensives. Losartan's three FDA-approved indications, each backed by large randomized trials, make coverage refusals uncommon for these uses [1][2].

Losartan received initial FDA approval in 1995 for hypertension [3]. The RENAAL trial (N=1,513) subsequently demonstrated a 16% reduction in the composite of doubling of serum creatinine, end-stage renal disease, or death in type 2 diabetic patients with nephropathy, supporting the 2001 label expansion [4]. The LIFE trial (Lancet 2002, N=9,193) showed losartan 50 to 100 mg reduced the primary composite endpoint of cardiovascular death, stroke, or myocardial infarction by 13% vs. Atenolol (RR 0.87; 95% CI 0.77, 0.98; P=0.021), with a particularly pronounced 25% relative reduction in stroke [5]. These data anchor the guideline support losartan enjoys today.

The 2023 American Heart Association/American College of Cardiology Hypertension Guideline endorses ARBs as first-line agents for patients with heart failure, chronic kidney disease, or diabetes [6]. Because CMS evaluates formulary adequacy against accepted clinical guidelines, plans that omit losartan entirely face compliance risk. In practice, every major carrier (UnitedHealthcare, Humana, Aetna, BCBS, Cigna) lists a generic ARB, and losartan or irbesartan is almost always the representative.

What Formulary Tier Is Losartan on Medicare Advantage?

Losartan sits on Tier 1 (preferred generic) or Tier 2 (non-preferred generic) on nearly every MA-PD formulary reviewed for 2024 and 2025 plan years. The precise tier varies by carrier and region, but the copay difference between tiers is small: the average Tier 1 generic copay across Part D plans is $1, $5, while Tier 2 averages $7, $15 [7].

Brand-name Cozaar, if a beneficiary requests it by name, carries a manufacturer list price near $80 per month and lands on Tier 3 or higher on most formularies. Plans may apply a brand copay of $40, $50 or more, and some apply non-preferred brand cost-sharing exceeding $90 per fill. Clinically, the generic is bioequivalent and FDA-rated AB, so there is no therapeutic reason to request the brand unless a patient has a documented excipient intolerance [8].

To confirm the exact tier for a specific plan: (1) use the CMS Plan Finder at medicare.gov/plan-compare, (2) enter your zip code and the drug name "losartan potassium," and (3) compare copays across plans side-by-side. This lookup takes roughly three minutes and reflects real-time formulary data submitted to CMS.

Prior Authorization for Losartan on Medicare Advantage

Prior authorization (PA) for losartan is rare when the prescription lists a covered indication. The FDA label supports three discrete uses, and all three carry strong guideline endorsement from the AHA, ACC, and American Diabetes Association (ADA). Plans that do impose PA for losartan typically require the prescriber to confirm the diagnosis code (ICD-10 I10 for hypertension, I50 for heart failure, N18 for CKD, or E11.65 for type 2 diabetes with CKD).

PA denial rates for generic ARBs in Part D are not tracked separately in CMS public data, but the agency's 2023 Part D Transparency Report noted that approximately 76% of all PA requests for generic drugs are approved on initial submission [9]. Rejections at the plan level most often occur when: the diagnosis code on the prescription is incomplete, the prescriber submits an NDC number for the brand instead of the generic, or the plan suspects off-label use (for example, losartan for weight reduction, which has no FDA approval and no large randomized trial supporting it in this population).

If a PA is requested, the prescriber should submit the patient's blood pressure logs, most recent basic metabolic panel (for renal function and potassium), and the relevant ICD-10 codes with supporting chart notes. CMS requires plans to respond to standard PA requests within 72 hours and urgent requests within 24 hours under 42 CFR §423.568 [10].

Step Therapy: Does Medicare Advantage Require It for Losartan?

Some MA-PD plans apply step therapy requiring a trial of an ACE inhibitor, typically lisinopril or enalapril, before approving losartan without restriction. The rationale is cost: lisinopril 10 mg costs pharmacies under $2 per 30-day supply at wholesaler prices, vs. Roughly $6, $8 for generic losartan. The difference is small, but multiplied across millions of members it drives formulary design decisions.

The 2018 SUPPORT Act and subsequent CMS rulemaking give Medicare Advantage enrollees a clear right to a step therapy exception if: (a) the required step-therapy drug is contraindicated, (b) the patient has already tried and failed the step drug, or (c) the step drug is expected to cause an adverse reaction [11]. ACE inhibitors cause a dry cough in 10 to 15% of patients and angioedema in roughly 0.1 to 0.3%, both of which constitute clinically valid reasons to skip to an ARB [12]. Prescribers should document any prior ACE inhibitor intolerance in the PA request letter.

Patients with bilateral renal artery stenosis, pregnancy, or a prior history of ACE-inhibitor-induced angioedema should proceed directly to an ARB, and these contraindications are generally sufficient for a step therapy exception without additional documentation.

Losartan for Weight Loss: Does Medicare Advantage Cover It?

No. Losartan is not FDA-approved for weight loss, and Medicare Advantage plans follow CMS's longstanding rule that Part D cannot cover drugs used primarily for weight reduction unless the drug also carries a separate cardiovascular outcomes indication [13]. Losartan's mechanism, blocking the angiotensin II type 1 receptor, does not produce clinically meaningful weight loss in randomized controlled trials. The LIFE trial recorded no significant difference in body weight between the losartan and atenolol arms at 4.8 years of follow-up [5].

Some observational data suggest ARBs may modestly improve insulin sensitivity, but no published RCT has demonstrated losartan producing weight loss that meets the FDA threshold of 5% or more mean body weight reduction vs. Placebo [14]. A plan that receives a prior authorization request listing weight loss as the primary indication will deny it, and an external appeal based solely on weight loss is unlikely to succeed because there is no FDA approval or major guideline recommendation to cite.

Patients with obesity who also have hypertension or diabetic nephropathy can receive losartan covered for those indications. The prescription should list the covered indication, not weight loss, as the primary diagnosis.

How to Appeal a Medicare Advantage Denial for Losartan

CMS defines a five-level appeals process for Part D coverage denials. Most denials for losartan are resolved at Level 1 or Level 2.

Level 1: Plan Redetermination. The enrollee or prescriber requests the plan reconsider within 60 days of the denial notice. The plan must respond within 7 days for standard requests and 72 hours for expedited requests [15]. Submit the prescriber's clinical notes, diagnosis codes, and any trial failure documentation.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case goes to MAXIMUS Federal Services, CMS's contracted IRE. MAXIMUS must resolve standard cases within 7 days and expedited cases within 72 hours. In 2022, Part D enrollees who reached the IRE level had their cases overturned at a rate of approximately 36% for formulary exceptions [16].

Level 3: Office of Medicare Hearings and Appeals (OMHA). An administrative law judge reviews the case if the disputed amount exceeds $180 (2024 threshold). This stage typically takes 90 to 180 days.

Level 4: Medicare Appeals Council.

Level 5: Federal District Court (if the disputed amount exceeds $1 to 840 in 2024).

For a $10/month generic like losartan, most appeals resolve at Level 1 or Level 2 before the cost threshold for OMHA becomes relevant. The fastest path is a prescriber-initiated expedited redetermination citing a specific contraindication to the step-therapy alternative.

Can You Use a Manufacturer Savings Card with Medicare Advantage?

No. Federal Anti-Kickback Statute regulations prohibit manufacturers from offering copay assistance cards or savings programs to Medicare or Medicaid beneficiaries. This applies to all Medicare Advantage plans regardless of carrier. A beneficiary who accepts a manufacturer coupon while enrolled in a federal program risks coverage termination and potential fraud liability [17].

Losartan's cash price is so low that manufacturer assistance is rarely necessary. At GoodRx-negotiated prices, a 90-day supply of losartan 50 mg costs approximately $15, $25 at national chains including CVS, Walgreens, Walmart, and Kroger. Mark Cuban's Cost Plus Drugs lists losartan 50 mg (90 tablets) at $9.40 as of early 2025. Patients who hit the Part D deductible early in the year may find cash pay cheaper than their plan copay for a brief window.

The Extra Help (Low Income Subsidy) program does apply to Medicare beneficiaries with incomes up to 150% of the federal poverty level. Under Extra Help, copays for generic drugs are capped at $4.50 per fill in 2024, making losartan effectively free for qualifying enrollees [18].

Losartan Dosing and Clinical Use Covered by Medicare

Understanding covered indications helps beneficiaries communicate accurately with their prescribers and plans.

Hypertension: Starting dose is 50 mg once daily; may be titrated to 100 mg once daily. Patients with intravascular volume depletion (for example, those on diuretics) should start at 25 mg [3].

Heart failure with reduced ejection fraction: The 2022 AHA/ACC/HFSA Heart Failure Guideline gives ARBs a Class I recommendation for patients who cannot tolerate ACE inhibitors; target dose for losartan in heart failure trials was 50 to 150 mg daily [19].

Diabetic nephropathy (type 2 diabetes with proteinuria): RENAAL used 50 to 100 mg daily. The FDA label specifies "type 2 diabetic patients with elevated serum creatinine and proteinuria" as the covered population [4].

These three indications cover the vast majority of clinical scenarios in which a Medicare-aged patient would receive losartan. Prescriptions written for any of these diagnoses should clear formulary review without incident on most plans.

Original HealthRX Coverage Framework for Losartan Under Medicare Advantage

The table below organizes the four most common losartan coverage scenarios a beneficiary or prescriber will encounter, the expected plan response, and the recommended action. This framework was developed by the HealthRX clinical team based on CMS formulary data, the 2024 Medicare Field Files, and the appeals timeline rules at 42 CFR §423.

| Scenario | Expected Plan Response | Recommended Action | |---|---|---| | Generic losartan for hypertension (ICD-10 I10) | Auto-adjudicated, no PA needed | Fill at any in-network pharmacy | | Generic losartan after documented ACE inhibitor cough | PA may be requested; approval likely | Submit chart note documenting cough; expect approval within 72 hours | | Losartan step therapy required, no prior ACE trial | PA denial possible | Prescriber submits step-therapy exception citing ACE intolerance or contraindication | | Losartan requested for weight loss only | Denial certain | Switch to FDA-approved weight-loss agent; list covered comorbidity if applicable |

Monitoring Requirements That May Affect Coverage Documentation

Plans and prescribers often overlook that ongoing losartan coverage can depend on documentation of appropriate monitoring. The FDA label for losartan in diabetic nephropathy recommends periodic serum creatinine and potassium monitoring because the drug reduces aldosterone and can cause hyperkalemia, particularly in patients with CKD or those taking potassium-sparing diuretics [3]. The incidence of hyperkalemia in RENAAL was 3.4% in the losartan arm vs. 1.9% in placebo (P<0.01) [4].

If a plan's utilization management algorithm flags a long-term losartan prescription without recent lab values on file, it may request clinical documentation before authorizing a refill. The 2022 KDIGO CKD Guideline recommends monitoring serum potassium and creatinine at 2 to 4 weeks after initiating or up-titrating an ARB in CKD patients [20]. Including recent lab results in PA documentation strengthens the case and reduces back-and-forth with the plan's pharmacy benefit manager.

Patients on losartan who also take trimethoprim-sulfamethoxazole, NSAIDs, or potassium supplements face additive hyperkalemia risk. Prescribers should document that this combination has been reviewed; some plans flag high-risk drug combinations as a trigger for utilization review.

How to Confirm Losartan Coverage Before Filling

Three steps take under five minutes and prevent a surprise rejection at the pharmacy counter.

First, call the Member Services number on the back of your insurance card and ask the representative to confirm that "losartan potassium" (NDC prefix 00093 for Teva's generic is one common option) is on your plan's formulary and what your specific tier copay is for a 30-day or 90-day supply.

Second, use the CMS Plan Finder (medicare.gov/plan-compare) to run the drug lookup yourself. The tool shows tier, copay, PA requirements, and quantity limits side-by-side across all plans in your zip code.

Third, ask your prescriber to send a 90-day supply prescription to a mail-order pharmacy if your plan offers a lower copay for mail order. Many MA-PD plans charge two copays for a 90-day mail-order fill rather than three, saving roughly $10, $30 per year on a Tier 1 generic.

The ADA's 2024 Standards of Care specify that clinicians should review medication cost and insurance access at every visit for patients with diabetes and CKD, given that treatment continuity directly affects renal and cardiovascular outcomes [21]. Losartan is explicitly named as a preferred ARB in this context, which provides strong documentation support if a plan questions medical necessity.